Logo image of SESN

SESEN BIO INC (SESN) Stock Fundamental Analysis

NASDAQ:SESN - Nasdaq - US8177631053 - Common Stock - Currency: USD

0.6288  +0.04 (+7.29%)

After market: 0.5832 -0.05 (-7.25%)

Fundamental Rating

3

Overall SESN gets a fundamental rating of 3 out of 10. We evaluated SESN against 561 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SESN as it has an excellent financial health rating, but there are worries on the profitability. SESN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

SESN had negative earnings in the past year.
In the past year SESN had a positive cash flow from operations.
SESN had negative earnings in each of the past 5 years.
In the past 5 years SESN always reported negative operating cash flow.
SESN Yearly Net Income VS EBIT VS OCF VS FCFSESN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M -40M -60M -80M -100M

1.2 Ratios

The profitability ratios for SESN are negative, so there is not much use analyzing them.
SESN has a better Return On Invested Capital (14.26%) than 97.33% of its industry peers.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC 14.26%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SESN Yearly ROA, ROE, ROICSESN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 100 -100 200 300 400

1.3 Margins

SESN has a better Operating Margin (49.65%) than 98.90% of its industry peers.
SESN's Operating Margin has improved in the last couple of years.
SESN does not have Profit Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM 49.65%
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5Y62.37%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SESN Yearly Profit, Operating, Gross MarginsSESN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -2K -4K -6K

More info and screens

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), SESN is creating some value.
SESN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SESN Yearly Shares OutstandingSESN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M
SESN Yearly Total Debt VS Total AssetsSESN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M

2.2 Solvency

SESN has an Altman-Z score of 1.65. This is a bad value and indicates that SESN is not financially healthy and even has some risk of bankruptcy.
SESN has a Altman-Z score of 1.65. This is in the better half of the industry: SESN outperforms 66.67% of its industry peers.
SESN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 1.65
ROIC/WACC1.61
WACC8.88%
SESN Yearly LT Debt VS Equity VS FCFSESN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M -50M 100M 150M

2.3 Liquidity

SESN has a Current Ratio of 5.54. This indicates that SESN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.54, SESN is in line with its industry, outperforming 49.06% of the companies in the same industry.
SESN has a Quick Ratio of 5.54. This indicates that SESN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.54, SESN is in line with its industry, outperforming 49.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.54
Quick Ratio 5.54
SESN Yearly Current Assets VS Current LiabilitesSESN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for SESN have decreased strongly by -364.00% in the last year.
The Revenue has grown by 816.87% in the past year. This is a very strong growth!
SESN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.41% yearly.
EPS 1Y (TTM)-364%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%455.56%
Revenue 1Y (TTM)816.87%
Revenue growth 3YN/A
Revenue growth 5Y-2.41%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SESN will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.42% on average per year.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y-308%
EPS Next 2Y4.02%
EPS Next 3Y19.21%
EPS Next 5Y12.42%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SESN Yearly Revenue VS EstimatesSESN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2020 2021 5M 10M 15M 20M 25M
SESN Yearly EPS VS EstimatesSESN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

SESN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SESN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SESN Price Earnings VS Forward Price EarningsSESN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

SESN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. SESN is cheaper than 97.96% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.31
EV/EBITDA -5.23
SESN Per share dataSESN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as SESN's earnings are expected to grow with 19.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.02%
EPS Next 3Y19.21%

More info and screens

0

5. Dividend

5.1 Amount

SESN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SESEN BIO INC

NASDAQ:SESN (3/7/2023, 7:50:19 PM)

After market: 0.5832 -0.05 (-7.25%)

0.6288

+0.04 (+7.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-28 2023-02-28/bmo
Earnings (Next)05-08 2023-05-08
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners1.16%
Ins Owner Change0%
Market Cap127.96M
Analysts43.33
Price Target12.24 (1846.56%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)100.94%
Min EPS beat(2)-20.66%
Max EPS beat(2)222.55%
EPS beat(4)3
Avg EPS beat(4)113.84%
Min EPS beat(4)-20.66%
Max EPS beat(4)222.55%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1900%
PT rev (3m)1900%
EPS NQ rev (1m)-1900%
EPS NQ rev (3m)-1900%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.13
P/FCF 13.31
P/OCF 13.31
P/B 0.78
P/tB 0.78
EV/EBITDA -5.23
EPS(TTM)-1.16
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)0.05
FCFY7.51%
OCF(TTM)0.05
OCFY7.51%
SpS0.29
BVpS0.81
TBVpS0.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC 14.26%
ROICexc N/A
ROICexgc N/A
OM 49.65%
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5Y62.22%
OM growth 3YN/A
OM growth 5Y62.37%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.54
Quick Ratio 5.54
Altman-Z 1.65
F-Score4
WACC8.88%
ROIC/WACC1.61
Cap/Depr(3y)25.56%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-364%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%455.56%
EPS Next Y-308%
EPS Next 2Y4.02%
EPS Next 3Y19.21%
EPS Next 5Y12.42%
Revenue 1Y (TTM)816.87%
Revenue growth 3YN/A
Revenue growth 5Y-2.41%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y485.82%
EBIT growth 3YN/A
EBIT growth 5Y58.47%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y126.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y126.61%
OCF growth 3YN/A
OCF growth 5YN/A